Loading…
Loading…
ASBP does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ASBP and 80,000+ other tickers.
See exactly how ASBP's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ASBP and 80,000+ other tickers.
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and…
ESTERO, FL / ACCESS Newswire / August 13, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), today announced that management will be present and host one-on-one meetings with investors at Sidoti & Company's Micro-Cap Virtual Investor Conference taking place on August 19-20, 2026. Management plans to discuss its clinical and commercial development pipeline and its recently closed acquisition of Dura Driver Control Systems, a leading global automotive supplier with a 100+ year history and $200M+ in 2025 revenue.
Acquisition represents a transformative milestone for Aspire, positioning the Company to rapidly evolve into a diversified, high-revenue enterprise Adds an established global brand with scale in large and growing markets driven by trends in vehicle and mobility control systems Augments revenue growth profile and diversifies Aspires' development and commercial portfolio with new high growth business Expected to immediately improve path to profitability ESTERO, FL / ACCESS Newswire / August 10, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), today announced that, the Company has completed its previously announced acquisition (the "Acquisition") of Dura Driver Control Systems ("DCS"), a tier-one supplier specializing in automotive systems that facilitate electronic driver control and the migration toward vehicle electrification, safety, lightweighting, and sustainability. The acquisition is expected to enhance Aspire's ability to deliver increased revenues, durable earnings and cash flow, driven by a new portfolio of product offerings in the large and growing markets for vehicle and mobility control systems.
Shares of Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP - Get Free Report) rose 10.9% on Monday. The stock traded as high as $7.44 and last traded at $7.23. 27,396 shares changed hands during trading, a decline of 49% from the average daily volume of 54,125 shares. The stock had previously closed at $6.52. Wall Street
High-Octane Partnership: Multi-time X Games medalist Jarryd McNeil joins BUZZ BOMB™ to fuel brand expansion in action sports. Consumer Connection: The collaboration strengthens BUZZ BOMB™'s commitment to delivering fast-acting energy to elite athletes and active consumers worldwide.
The brand expands nationwide distribution on Amazon, delivering a waterless, rapid-dissolve 50 mg caffeine powder built for active, on-the-go lifestyles. ESTERO, FL / ACCESS Newswire / June 24, 2026 / Aspire Biopharma Holdings, Inc.'s (Nasdaq:ASBP) ("Aspire" or the "Company") wholly owned subsidiary Buzz Bomb Caffeine Company LC today announced the nationwide Amazon launch of its innovative BUZZ BOMB™ 50mg caffeine stick packs.